Ozomet-VG 1 Tablet SR is a combination oral antidiabetic medication containing Glimepiride (1 mg), Metformin (500 mg), and Voglibose (0.2 mg), formulated for sustained release to optimize glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to enhanced glucose uptake and utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption in the intestines, attenuating postprandial hyperglycemia. The combined pharmacodynamic effects of these agents address multiple pathophysiological defects in type 2 diabetes, offering comprehensive glycemic management. Ozomet-VG 1 Tablet SR is indicated as adjunctive therapy to diet and exercise to improve glycemic control in adults inadequately controlled on monotherapy or dual therapy. The sustained-release formulation ensures gradual drug release, minimizing gastrointestinal side effects commonly associated with Metformin and Voglibose, and improving patient compliance. Dosage should be individualized based on patient response and tolerability, with regular monitoring of blood glucose and renal function. Contraindications include type 1 diabetes, diabetic ketoacidosis, significant renal or hepatic impairment, and hypersensitivity to any component. This combination therapy should be used under medical supervision to optimize efficacy and safety.